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Background: A standard treatment for unresectable advanced-stage intrahepatic cholangiocarcinoma (IHCC) has
not yet been established. Although neoadjuvant concurrent chemoradiotherapy (CCRT) and liver transplantation are
associated with long-term survival in select patients, the outcomes of CCRT for advanced-stage unresectable IHCC
remain unclear. The aim of our study was to evaluate the outcomes of CCRT in patients with unresectable
advanced-stage IHCC.
Methods: We retrospectively reviewed the records of all patients with unresectable advanced stage (stage IVa or
IVb) IHCC who were pathologically diagnosed and treated at National Cancer Center, Korea, from June 2001 to
March 2012. Of the total of 92 patients, 25 (27.1%) received capecitabine plus cisplatin (XP) chemotherapy with
external radiotherapy (RT) (XP-CCRT group) and 67 (72.8%) received XP chemotherapy alone (XP group). The clinical
characteristics and outcomes of the 2 groups were compared.
Results: The 92 patients comprised 72 male and 20 female patients, with a median age of 58 years (range 26–78 years).
The baseline clinical characteristics of the 2 groups were similar. Patients in the XP-CCRT group received a mean 44.7 Gy
of RT and a mean 5.6 cycles of XP chemotherapy, whereas patients in the XP group received a mean 4.0 cycles. The
disease control rate was higher in the XP-CCRT group than in the XP group, but the difference was not statistically
significant (56.0% vs. 41.5%, p = 0.217). Although neutropenia was significantly more frequent in the XP-CCRT than in
the XP group (48% vs. 9%, p < 0.001), the rates of other toxicities and > grade 3 toxicities did not differ. At a median
follow-up of 5.3 months, PFS (4.3 vs. 1.9 months, p = 0.001) and OS (9.3 vs. 6.2 months, p = 0.048) were significantly
longer in the XP-CCRT than in the XP group.
Conclusions: XP-CCRT was well tolerated and was associated with longer PFS and OS than XP chemotherapy alone in
patients with unresectable advanced IHCC. Controlled randomized trials are required to determine whether XP-CCRT is a
primary treatment option for patients with unresectable advanced IHCC.
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Figure 1 Patient flow chart.
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Intrahepatic cholangiocarcinoma (IHCC) is a cancer
arising from the intrahepatic bile duct, between the per-
iphery of the liver and the second order bile duct. IHCC
is the second most frequent type of primary liver cancer,
after hepatocellular carcinoma [1]. The incidence of and
mortality associated with IHCC have been increasing,
but its prognosis remains poor because of a lack of ef-
fective treatment options [2-5]. Although surgical resec-
tion is potentially curative, more than half of these
patients are at an advanced stage at the time of diagnosis
and therefore have dismal prognosis. Resectability rates
are generally quite low, but vary from 18%–70% [6]. The
5-year survival rate after surgery is modest at approxi-
mately 30% [7-9].
A large observational study reported that the median
survival of untreated patients with advanced-stage, unre-
sectable IHCC was 3 months [10]. To date, however, a
treatment strategy for these patients has not yet been stan-
dardized. Palliative systemic chemotherapy has been found
to prolong median survival compared with supportive care
alone [11,12]. Neoadjuvant concurrent chemoradiotherapy
(CCRT) followed by liver transplantation has been re-
ported to be effective for select patients with early-stage
unresectable perihilar cholangiocarcinoma [13,14] and lo-
cally advanced IHCC [15,16]. Although CCRT has been
also found to improve survival in patients with advanced-
stage unresectable perihilar or extrahepatic cholangiocar-
cinoma [17,18], it is not clear if CCRT also prolongs
survival in patients with advanced-stage unresectable
IHCC. We have therefore retrospectively compared out-
comes, including response rate, progression-free survival
(PFS), overall survival (OS), and safety, in patients with
advanced-stage unresectable IHCC, including those with




Hospital records of 485 patients who were pathologically
diagnosed, by ultrasonography-guided percutaneous liver
biopsy, with IHCC at the National Cancer Center, Korea,
from June 2001 to March 2012 were retrospectively
reviewed. IHCC resectability was determined by clinical
and radiographic findings, with extensive bilobular
invasion, major vessel involvement, and extrahepatic
metastases considered markers of unresectable disease.
Of the 132 patients with advanced-stage unresectable
IHCC who received palliative systemic chemotherapy, 92
(69.7%) were treated with capecitabine plus cisplatin
(XP) and were retrospectively analyzed. All patients were
found to have stage IVa (46.7%) or IVb (53.3%) disease
according to the seventh edition of the American Joint
Committee on Cancer-TNM staging system [19]. Of the92 included patients, 25 (27.2%) received XP chemother-
apy with concurrent radiotherapy (XP-CCRT group) and
67 (72.8%) received XP chemotherapy alone (XP group).
Patients who underwent surgical resection, those who
were treated with other chemotherapy regimens, and
those who received supportive care alone were excluded
(Figure 1). The present study was approved by the Insti-
tutional Review Board of the National Cancer Center,
Korea (NCCNCS-12-686), and was conducted in accord-
ance with the guidelines of the International Conference
on Harmonization/Good Clinical Practice and the prin-
ciples of the Declaration of Helsinki.
Chemotherapy
Each patient received 1000 mg/m2 oral capecitabine
twice daily for the first 14 days of each 21-day cycle,
followed by a 7-day rest period, together with 30 mg/m2
intravenous cisplatin for 1 hour with standard hydration
on days 1 and 8 of each cycle [20]. Patients were contin-
ued on XP chemotherapy until progressive disease or
the development of severe toxicity.
Radiotherapy
Among included patients, 25 patients underwent concur-
rent RT. Eligible criteria for RT included: 1) radiographic-
ally assessable disease, 2) adequate laboratory findings
including common blood cell counts (white blood cell
≥ 2,000/mm3, hemoglobin ≥ 7.5 g/dL, platelet ≥ 100,000/
mm3), total bilirubin ≤ 3.0 mg/dL, serum creatinine
≤ 1.5 mg/dL), 3) adequate oral intake of 1,500 calories/day.
Meanwhile, exclusion criteria for RT were as follows:
1) previous history of RT adjacent to the planned RT field,
2) multifocal intrahepatic lesions which did not covered
by planned RT field.
Planning of external beam radiotherapy (RT) was based
on radiographic findings from abdominal computed






Median age at diagnosis, years
(range)
56 (32 – 75) 58 (26 – 78)
Sex, n (%)
Male 19 (76.0) 53 (79.1)
Female 6 (24.0) 14 (20.9)
ECOG, n (%)
0 10 (40.0) 39 (58.2)
1 14 (56.0) 24 (35.8)
2 1 (4.0) 4 (6.0)
Tumor stage, n (%)
Stage IVa 14 (56.0) 29 (43.3)
Stage IVb 11 (44.0) 38 (56.7)
Tumor characteristics
Maximum diameter, cm 7.6 ± 3.9 7.4 ± 3.1
Location of intrahepatic lesions, n (%)
Unifocal 18 (72.0) 27 (40.7)
Multifocal 7 (28.0) 40 (59.7)
Radiographic gross type, n (%)
Mass-forming 22 (88.0) 57 (85.1)
Periductal infiltrative 3 (12.0) 10 (14.9)
LN metastasis, n (%) 21 (84.0) 55 (82.1)
Extrahepatic metastasis, n (%) 11 (44.0) 38 (56.7)
CA 19–9, U/mL 1684.7 ± 4881.2 3121.7 ± 9622.1
CEA, ng/mL 26.5 ± 53.9 190.3 ± 764.0
Data expressed as number (%) or mean ± standard deviation.
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The gross tumor volume was defined by these planning
imaging studies. Then, the clinical target volume included
the gross tumor volume and the volumes of adjacent
lymph nodes (LNs) in the porta hepatis, celiac axis, and
pancreaticoduodenal ligament, regardless of the presence
of extrahepatic metastases. The clinical target volume and
gross tumor volume plus a 5–10 mm margin were in-
cluded in the initial and boot planning target volume. Of
the 25 patients in this group, 18 (72.0%) were treated with
3-dimensional conformal RT using 2–4 ports, 5 (20.0%)
received intensity-modulated RT using 2–5 ports, and 2
(8.0%) received proton beam RT using 2 ports. All these
patients underwent a CT simulation in the treatment pos-
ition. In this treatment planning, the planning target vol-
ume would be encompassed by a 90% iso-dose volume of
the prescribed dose.
Concurrent RT was applied in single fractions of 2.0–
3.0 Gy once a day and 5 times a week, with a mean total
RT dose of 44.7 Gy (range 25.0–60.0 Gy). Although
usual target doses were between 37.5 Gy and 50.0 Gy,
several fractions of booster RT were performed in some
well-tolerate patients with limit dose of 60.0 Gy.
Follow-up and assessment of tumor response and toxicity
Patients were evaluated by physical examination and
assessments of complete blood counts and blood chem-
istry after each cycle. Abdominal CT was performed
after every 2 cycles of chemotherapy to measure tumor
response, which was classified according to the Re-
sponse Evaluation Criteria in Solid Tumor (RECIST)
guidelines [21]. PFS was defined as the time from diag-
nosis to the development of progressive disease (PD) or
death whichever came first. Toxicity was monitored ac-
cording to the Common Terminology Criteria for Ad-
verse Events (CTCAE) v3.0.
Statistical analysis
Comparisons between 2 groups were evaluated using
Student’s t tests for continuous variables or chi-square
tests for categorical variables, as appropriate. The
follow-up period of each patient was defined from the
time of diagnosis to the time of last visit or discharge
from hospital. Among 92 patients included in this study,
91 were dead, and the death dates of patients who did
not die in hospital were obtained from the claim data-
base of Korean National Health Insurance Corporation
after permission of data access. Estimated OS and radio-
graphic PFS were calculated from the time of diagnosis
using the Kaplan-Meier method and analyzed using
log-rank tests. All statistical analyses were performed
using STATA 12.1 for Windows (Stata Corp, College
Station, TX, USA). A p value of <0.05 was considered
statistically significant.Results
Patient characteristics
Table 1 shows the baseline clinical characteristics of the
92 enrolled patients. Of these patients, 72 (78.3%) were
male and 20 (21.7%) were female; their median age was
58 years (range 26–78 years). Eighty-seven patients
(94.6%) had good performance status (Eastern Coopera-
tive Oncology Group [ECOG] scale 0 or 1). The mean
maximum tumor size was 7.3 cm, and the mean serum
concentrations of carbohydrate antigen (CA) 19–9 and
carcinoembryonic antigen (CEA) were 2675.4 U/mL and
107.7 ng/mL, respectively. Evaluation using the morpho-
logic classification system proposed by the Liver Cancer
Study Group of Japan [22] indicated that 79 (85.9%) pa-
tients had mass-forming type and 13 (14.1%) had peri-
ductal infiltrative type IHCC. In addition, 76 patients
(82.6%) had LN metastasis and 49 (53.3%) had extrahe-
patic metastasis. Patients in XP-CCRT group had signifi-
cantly higher rate of single intrahepatic lesion than those
Figure 2 Kaplan-Meier estimates of progression-free survival
(A) and overall survival (B) in the XP-CCRT and XP groups.
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baseline clinical characteristics of the XP-CCRT and XP
groups did not differ significantly.
Tumor response and outcomes
Patients in the XP-CCRT group received more cycles of
chemotherapy than those in the XP group (5.6 vs. 4.0 cy-
cles, p = 0.082). Of the 92 patients, tumor response could
not be assessed in 2 patients because of a lack of follow-up
CT data. Of the 90 patients evaluable for tumor response,
4 (4.4%) had a partial response (PR) and 37 (41.1%) had
stable disease (SD). Disease control rate (DCR), which
accounted for patients with complete response (CR), PR,
and SD, was higher in the XP-CCRT than in the XP group,
although the difference was not statistically significant
(56.0% vs. 41.5%, p = 0.217) (Table 2).
The median follow-up duration of the 92 patients was
5.3 months (interquartile range [IQR], 3.0–9.5 months).
The median PFS for all patients was 2.6 months (95%
confidential interval [CI] 2.0–3.2 months), and the me-
dian OS was 7.9 months (95% CI 5.8–10.0 months). Me-
dian PFS (4.3 vs. 1.9 months, p = 0.001) and OS (9.3 vs.
6.2 months, p = 0.048) were significantly longer in the
XP-CCRT than in the XP group (Figure 2, Table 2), but
the 1-year survival rates did not differ significantly
(30.4% vs. 22.4%, p = 0.438).
Toxicity
The rates of hematologic and non-hematologic toxicities
are listed in Table 3. Neutropenia and hand-foot syn-
drome were more frequent in the XP-CCRT than in the
XP group. However, the frequency of grade 3 and 4 tox-
icities did not differ between the groups. In the XP-








5.6 ± 5.8 4.0 ± 3.2 0.082
Tumor response (n = 90),
n (%)
0.365
CR 0 (0) 0 (0)
PR 1 (4.0) 3 (4.6)
SD 13 (52.0) 24 (36.9)
PD 11 (44.0) 38 (58.5)
Disease-control rate
(CR + PR + SD)
14 (56.0) 27 (41.5) 0.217
Median FU duration,
months (IQR)
7.4 (4.1 – 15.1) 4.1 (2.3 – 8.3) 0.044
Median PFS, months (95% CI) 4.3 (3.3 – 5.4) 1.9 (1.3 – 2.4) 0.001*
Median OS, months (95% CI) 9.3 (7.6 – 11.0) 6.2 (4.1 – 8.2) 0.162*
*By log-rank test.




(n = 67) p-value
Hematologic toxicity
Neutropenia 12 (48.0) 6 (9.0) < 0.001
Thrombocytopenia 17 (68.0) 36 (53.7) 0.218
Anemia 13 (52.0) 25 (37.3) 0.203
Non-hematologic toxicity
Anorexia 16 (64.0) 28 (41.8) 0.058
Nausea 8 (32.0) 16 (23.9) 0.430
Vomiting 3 (12.0) 5 (7.5) 0.678
Asthenia 6 (24.0) 28 (41.8) 0.116
Dyspnea 17 (68.0) 36 (53.7) 0.218
Peripheral neuropathy 3 (12.0) 3 (4.5) 0.339
Hand-foot syndrome 6 (24.0) 3 (4.5) 0.011
>Grade 3 toxicity 6 (24.0) 7 (10.4) 0.174
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and 1 (4.0%) had grade 4 hand-foot syndrome. Treat-
ment was well tolerated in both treatment groups and
there were no treatment-related deaths.
Discussion
Patients with unresectable IHCC may be eligible for local-
regional therapy, systemic chemotherapy, and best sup-
portive care. Local-regional therapies for these patients
include RT, transarterial chemoembolization, and radiofre-
quency ablation, but few studies to date have evaluated
their efficacy in patients with unresectable IHCC. To our
knowledge, this is the first study to assess the outcomes of
CCRT in patients with stage IVa/IVb IHCC. We found
that the combination of XP chemotherapy and external
beam RT was well tolerated and resulted in prolonged PFS
and OS compared with XP alone. CCRT outcomes have
been reported in patients with extrahepatic cholangiocar-
cinoma [17,18,23,24], and CCRT did not significantly en-
hance benefits, compared with RT alone, in patients with
unresectable extrahepatic biliary cancer [25]. Prospective
randomized trials are therefore needed to confirm the
benefits of CCRT in patients with advanced-stage unre-
sectable biliary tract cancer.
A recent retrospective study showed that external
beam RT prolonged survival and relieved the symptoms
of jaundice in patients with early-stage but unresectable
IHCC, with a median OS of 9.5 months and a 1-year OS
rate of 38.5% [26]. However, CCRT may be more benefi-
cial than loco-regional RT alone for patients with
advanced-stage unresectable IHCC, including those with
distant metastases. The CCRT group in our study, which
included 11 patients (44%) with extrahepatic metastases,
had better outcomes than the group receiving XP alone.
Because of the small number of patients, however, we
could not analyze the prognostic factors, such as distant
metastasis, associated with OS and PFS.
Although systemic chemotherapy has been reported su-
perior to best supportive care [11,12], a standard chemo-
therapy regimen has not yet been established in patients
with advanced, unresectable IHCC, because of the lack of
randomized, prospective trials [27]. A recent phase III
randomized controlled trial showed that the combination
of gemcitabine and cisplatin (GP chemotherapy) was
highly effective in patients with locally advanced or meta-
static biliary tract cancer, including in patients with recur-
rent disease after resection [28]. Because on a few patients
in our center received GP chemotherapy, we analyzed pa-
tients treated with XP chemotherapy. In phase II trials, XP
chemotherapy was shown to be an active and well-
tolerated first-line regimen in patients with advanced
biliary tract cancer [29,30].
XP has also shown good radio-sensitizing activity in
patients with gastrointestinal malignancies [31]. Ourfindings indicated that CCRT may be better option for
patients with advanced-stage unresectable IHCC than
systemic chemotherapy alone. The better outcomes ob-
served with XP-CCRT may have been because of the
synergistic effects of RT and systemic chemotherapy.
Moreover, except for neutropenia, the frequencies of
treatment-related toxicity and >3 grade toxicity (24% vs.
10.4%, p = 0.174) were not significantly higher in the XP-
CCRT than in the XP group, despite the former group
receiving more cycles of chemotherapy as well as RT.
These findings indicate that XP-CCRT is safe for pa-
tients with advanced-stage, unresectable IHCC.
This study had several limitations, including the small
number of patients and its retrospective design. Thus,
selection bias is inevitable. Moreover, the RT method
and total dose differed among patients in the XP-CCRT
group. Nevertheless, the significant improvements in
PFS and OS observed with CCRT suggest the need for
randomized prospective clinical trials comparing the dif-
ferent chemotherapy regimens (e.g., GP vs. XP) in com-
bination with RT.
Conclusion
XP-CCRT was well tolerated and resulted in prolonged
PFS and OS compared with XP chemotherapy alone in
patients with unresectable advanced IHCC. Controlled
randomized trials are required to determine whether
XP-CCRT should be a primary treatment option for
these patients.
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